Skip to main content
SpringerLink
Log in

Aldosterone and Myocardial Infarction—Are Aldosterone Antagonists Needed to Prevent Remodelling or Does Ace Inhibition Suffice?

  • Editorial Board
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995; 91: 2043-2048.

    PubMed  Google Scholar 

  2. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodelling after myocardial infarction in the rat. Circulation 1994; 89: 2273-2282.

    PubMed  Google Scholar 

  3. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of theSOLVDechocardiography substudy. Circulation 1995; 91: 2573-2581.

    PubMed  Google Scholar 

  4. Doughty R, Whalley G, MacMahon S, et al. Carvedilol reduces left ventricular volumes in patients with heart failure of ischemic origin. J Am Coll Cardiol 1994; 24: 1762-1768.

    PubMed  Google Scholar 

  5. Groenning BA, Nillson JC, Sondergaard L, Fritz-Hansen T, Larsson HBW, Hildebrandt PR. Antiremodeling effects in the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36: 2072-2080.

    PubMed  Google Scholar 

  6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodelling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 67: 1355-1364.

    PubMed  Google Scholar 

  7. Sivestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction. Circulation 1999; 99: 2694-2701.

    PubMed  Google Scholar 

  8. Di Pasquale P, Cannizzarro S, Scandurra A, Giubilato A, Scalzo S, Paterna S. ACE-inhibition plus mineralocorticoid antagonism versus ACE-inhibition alone in patients with anterior myocardial infarction. Cardiovasc Drugs Ther 2001; 15: 309-314.

    PubMed  Google Scholar 

  9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.

    PubMed  Google Scholar 

  10. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Ther 2001; 15: 79-87.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands

    Willem J. Remme

Authors
  1. Willem J. Remme
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remme, W.J. Aldosterone and Myocardial Infarction—Are Aldosterone Antagonists Needed to Prevent Remodelling or Does Ace Inhibition Suffice?. Cardiovasc Drugs Ther 15, 297–298 (2001). https://doi.org/10.1023/A:1012746312309

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012746312309

Search

Navigation